Cue Biopharma Culture d’entreprise

Dr. Rodolfo J. Chaparro, Ph.D. serves as an Executive Vice President and Head of Immunology at Cue Biopharma, Inc. Dr. Chaparro is co-founder of Cue Biopharma and co-inventor of Cue's technologies. Dr. Chaparro has oversight of Cue's immuno-oncology and autoimmunity research programs as well as Cue's preclinical and early clinical development. Dr. Chaparro was a research faculty member in the Department of Biochemistry at the Albert Einstein College of Medicine in New York. Dr. Chaparro possesses research expertise in molecular immunology and immunotherapeutics development and was Head of Immunology within its Macromolecular Therapeutics Development Facility (MTDF). Dr. Chaparro holds a B.S. in Biology from the University of California at Irvine and a Ph.D. in immunology from Stanford University.

Mr. Gary A. Schuman has been Interim Chief Financial Officer at Cue Biopharma, Inc since March 2015. He joined MDB Capital Group in 2009. Leveraging more than 18 years of securities industry experience where he has been instrumental in the launch of several investment firm start-ups, including hedge funds, broker-dealers and investment advisors, Mr. Schuman is responsible for all financial reporting, compliance and general administration at MDB. From 2003 to 2008, Mr. Schuman was the Chief Financial Officer and Chief Compliance Officer of USBX Advisory Services, LLC, an investment banking firm focused on mergers and acquisitions and Chief Financial Officer of its parent company, USBX, Inc., from 2003 to 2009. He is also the Chief Financial Officer and Chief Compliance Officer of MDB. Mr. Schuman has been with MDB since November 2009. From May 2014 to November 2015, Mr. Schuman served as Chief Financial Officer of Pulse Biosciences, Inc. From 2010 to April 2017, Mr. Schuman served as Chief Financial Officer of Integrated Surgical Systems, Inc., known as theMaven, Inc. Mr. Schuman also served in several managerial capacities at Equibond, Inc. Mr. Schuman received a Bachelor of Arts degree in Economics from UCLA and an MBA from the Marshall School of Business at the University of Southern California.

Dr. Steven C. Almo, Ph.D. is a Founder of Cue Biopharma, Inc. and serves as its Chairman of Scientific & Clinical Advisory Board. Dr. Almo is the Chairman of the Department of Biochemistry at Albert Einstein College of Medicine/Montefiore Medical Center, where he is Professor of Biochemistry and of Physiology & Biophysics. Dr. Almo holds the Wollowick Family Foundation Chair in Immunology and is Director of Einstein's Macromolecular Therapeutics Development Facility, a resource dedicated to the development and optimization of protein-based therapeutics. Dr. Almo is recognized for his broad contributions to structural biology and has published more than 300 papers. His laboratory has played key roles in the development and implementation of high-throughput approaches for protein production, structure determination and functional annotation. Dr. Almo received his Ph.D. in Biophysics from Harvard University, while working with Greg Petsko in the Chemistry Department at MIT.

Dr. Ronald D. Seidel, III, also known as Ron, Ph.D. serves as an Executive Vice President and Head of Research & Development at Cue Biopharma, Inc. Dr. Seidel is co-founder of Cue Biopharma and co-inventor of Cue's technologies. Dr. Seidel has oversight of daily company operations, including integrating R&D and intellectual property (IP) development strategy with operational capabilities and scientific direction. Specifically, he leverages expertise in molecular engineering towards the generation of new high value assets. Previously Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. The function of the MTDF was to leverage high throughput technologies for the development, analysis and production of protein-based therapeutics. Additionally, through the MTDF, Dr. Seidel was the Associate Director of Eukaryotic Protein Production at the Northeast BioDefense Center (NBC). He served as Consultant to industry in biologics and protein production. He did his post-doctoral work at the New York Structural Biology Center. Dr. Seidel holds a B.S. and Ph.D. in biochemistry from the University of Georgia.